Physician profile
Sanjay Sharma
NPI 1265606552
$38,758.92
in general payments reported to CMS, 2019-2025
40 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,090 · 2020: $2,216 · 2021: $4,459 · 2022: $11K · 2023: $6,124 · 2024: $8,856 · 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $6,080 · Travel and Lodging: $497 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,355.93 |
| Consulting Fee | $6,080.00 |
| Travel and Lodging | $496.60 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,949.93 | 2019-2024 | Trodelvy |
| Abiomed | $7,818.43 | 2019-2025 | Impella |
| Abbott Laboratories | $6,184.28 | 2019-2024 | Amplatzer Amulet, Pressurewire, Perclose Prostyle |
| Boston Scientific Corporation | $2,673.19 | 2019-2025 | Emblem Mri S-Icd, Resonate El Icd Vr, Watchman Access System |
| Medtronic, INC. | $1,484.62 | 2021-2025 | Micra, Onyx Frontier, Linq II |
| Array Biopharma INC | $1,400.00 | 2025 | Braftovi |
| Novartis Pharmaceuticals Corporation | $1,268.93 | 2020-2025 | |
| Edwards Lifesciences Corporation | $1,053.36 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Philips North America LLC | $1,022.24 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,000.40 | 2019-2025 | Farxiga, Brilinta |
| Cvrx, INC. | $900.27 | 2021-2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $387.19 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $355.75 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $251.46 | 2020-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.17 | 2023 | Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.